Immuron Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Steve Lydeamore

İcra Kurulu Başkanı

AU$599.1k

Toplam tazminat

CEO maaş yüzdesi	72.7%
CEO görev süresi	2.4yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	5.9yrs
Yönetim Kurulu ortalama görev süresi	5.1yrs

Son yönetim güncellemeleri

Recent updates

Immuron suspends research on COVID-19 program

Aug 19

Immuron says proposed trials of antibacterial drug put on clinical hold by FDA

Jul 26

Immuron to get European patent for drug composition to treat bacterial infection

Jul 07

Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%

Dec 15

Immuron soars 26% on positive vaccine responses in gut mediated pathogens

Nov 11

CEO Tazminat Analizi

Steve Lydeamore'un ücretlendirmesi Immuron'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$599k	AU$436k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$4m
Sep 30 2023	n/a	n/a	-AU$4m
Jun 30 2023	AU$584k	AU$415k	-AU$4m
Mar 31 2023	n/a	n/a	-AU$3m
Dec 31 2022	n/a	n/a	-AU$3m
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	AU$781k	AU$6k	-AU$3m

Tazminat ve Piyasa: Steve 'nin toplam tazminatı ($USD 390.27K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 652.28K ).

Tazminat ve Kazançlar: Steve şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Steve Lydeamore (56 yo)

2.4yrs

Görev süresi

AU$599,135

Tazminat

Mr. Steven George Lydeamore, also known as Steve, MBA, CPA, serves as Chief Executive Officer at Immuron Limited since June 27, 2022. He served as the Chief Executive Officer of Anatara Lifesciences Limite...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Steven Lydeamore	Chief Executive Officer	2.4yrs	AU$599.14k	Veri yok
Jerry Kanellos	Chief Operating Officer	9.3yrs	AU$359.25k	0.15% $ 16.3k
Flavio Palumbo	Chief Commercial Officer	2yrs	AU$347.61k	Veri yok
Phillip Hains	CFO & Company Secretary	11.6yrs	Veri yok	0.36% $ 39.9k
David Lyon	Head of Marketing	no data	Veri yok	Veri yok

5.9yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim: IMRN 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Glenn Tillotson	Member of Advisory Board	no data	Veri yok	Veri yok
Jeannette Joughin	Independent Non-Executive Director	less than a year	AU$7.55k	0% $ 0
Daniel Pollock	Independent Non-Executive Director	12.1yrs	AU$127.65k	0.36% $ 40.0k
Paul Brennan	Independent Non-Executive Chairman	2.7yrs	AU$153.60k	0% $ 0
Dena Lyras	Member of Advisory Board	no data	Veri yok	Veri yok
Ravi Savarirayan	Independent Non-Executive Director	7.6yrs	AU$75.00k	0.38% $ 42.9k
Sahil Khanna	Member of Advisory Board	no data	Veri yok	Veri yok
Paul Feuerstadt	Member of Advisory Board	no data	Veri yok	Veri yok
Teena Chopra	Member of Advisory Board	no data	Veri yok	Veri yok

5.1yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IMRN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.1 yıldır).

Immuron Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited, Annual General Meeting, Oct 28, 2022

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Immuron Limited, Annual General Meeting, Oct 28, 2022

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Immuron suspends research on COVID-19 program

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron says proposed trials of antibacterial drug put on clinical hold by FDA

Immuron to get European patent for drug composition to treat bacterial infection

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron soars 26% on positive vaccine responses in gut mediated pathogens

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş